500–2,000 mg/day. Best in the morning: it can be activating.
May reduce neuropathic pain, especially in early stages.
View the study (RCT) →Improves depressive symptoms with very good tolerability; small studies.
View the study (meta-analysis) →Weak signal; it is not an established treatment.
⏱ 3 min read
Acetyl-L-carnitine, known in the literature as ALCAR, is a special form of L-carnitine to which an acetyl group is added that allows it to cross the blood-brain barrier much more easily than conventional carnitine, which makes it the form of choice when the goal is to work on the brain, the peripheral nerves, or mood, and not only on muscle energy metabolism.
Once inside the brain, ALCAR acts as an acetyl group donor for the synthesis of acetylcholine (the most important neurotransmitter for memory and attention), facilitates the mitochondrial transport of fatty acids in neurons, and modulates the expression of several neuronal growth factors, which explains its activity profile on cognition, neuropathy, and mood in different clinical contexts.
Several randomized trials in older adults with mild cognitive impairment have shown modest but significant improvements in tests of memory, attention, and processing speed at doses of 1.5 to 3 grams per day for 3 to 12 months; the effects are more consistent in people with incipient cognitive impairment than in healthy young adults, whose baseline is already close to the ceiling of possible performance.
In mild to moderate Alzheimer's disease, the available meta-analyses suggest a small benefit on cognitive symptoms and the rate of progression, enough for some neurology guidelines to mention it as a reasonable adjunct in selected people, though never as a substitute for acetylcholinesterase inhibitors or other interventions with better-established efficacy.
The clinical indication with the best evidence for ALCAR is not cognition but peripheral neuropathy of various causes: in painful diabetic neuropathy, in chemotherapy-induced neuropathy, and in HIV neuropathy, randomized trials have shown significant reductions in pain, improvements in nerve conduction, and, in some cases, partial recovery of sensation at doses of 2 to 3 grams per day over months.
The most plausible mechanism for this neurotrophic effect combines the supply of acetyl groups for myelin regeneration, improved neuronal energy metabolism, and modulation of glutamatergic receptors involved in the central sensitization of pain; it is one of the few over-the-counter compounds with clear clinical evidence for neuropathic pain, a condition that conventional medicine treats poorly and with significant adverse effects.
In mild to moderate geriatric depression, several trials have shown antidepressant effects comparable to those of traditional antidepressants with fewer adverse effects, especially in older people for whom SSRIs are sometimes poorly tolerated or have interactions with cardiovascular polypharmacy; in chronic fatigue, the data are less solid, but some people report notable improvements in their sense of mental energy.
The effective doses in clinical trials range from 1.5 to 3 grams per day, divided into two or three doses, ideally in the morning and at midday to avoid the activating effect that can interfere with sleep if taken late; perceptible clinical effects usually appear between 4 and 12 weeks, and it is not an immediate-acting compound like caffeine.
It is generally well tolerated; the most frequent adverse effects are nausea, agitation, insomnia if taken late, and a characteristic body odor (as with L-carnitine); people with bipolar disorder should use caution because of the theoretical risk of inducing mania or hypomania, and those taking acenocoumarol or warfarin should discuss it with their doctor because cases of interaction with anticoagulants have been described.
Information, not medical advice. Scientific evidence reflects the quality of the studies.